Clinical trials: Cervical Carcinoma
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00423046
- Testing
- GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc)
- Where
- 40 sites in United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Melanoma, Non-Small Cell Lung Cancer
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in…
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT03289962
- Testing
- Autogene cevumeran, Atezolizumab
- Where
- 33 sites in United States, Belgium and 6 more
- Volunteers
- 273 people
- Sponsor
- Genentech, Inc.
Human Papillomavirus
Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening
A prospective multicenter interventional study will be conducted to enroll women undergoing routine cervical cancer screening to collect cervical liquid-based cytology (LBC) specimen(s).
- Trial name
- NCT04746872
- Testing
- Alinity m HR HPV
- Where
- 63 sites in United States
- Volunteers
- 14,935 people
- Sponsor
- Abbott Molecular
Advanced Squamous Tumors
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy…
- Trial name
- NCT07241039
- Testing
- ABBV-711, Budigalimab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 220 people
- Sponsor
- AbbVie
Human Papilloma Virus, Human Papilloma Virus Related Cervical Carcinoma
Validation of Vaginal Self-Sampling With the Abbott Multi-Collect Swab for HPV Screening in Women Aged 30 to 64 Years
This study evaluates the performance of HPV testing on vaginal self-collected samples obtained with the Abbott Multi-Collect device.
- Conditions
- Human Papilloma Virus, Human Papilloma Virus Related Cervical Carcinoma, Cervical Carcinoma
- Trial name
- VALMUDES (NCT07768787)
- Testing
- Abbott Multi-Collect Specimen Collection Swab
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- AML
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
The primary purpose of the study is to determine if GARDASIL™ (V501) is able to prevent cervical cancer.
- Trial name
- FUTURE II (NCT00092534)
- Testing
- Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine
- Volunteers
- 12,167 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Cancer of Head and Neck
Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer
The purpose of this study is to determine the safety and tolerability of GL-ONC1 administered intravenously in combination with radiation therapy and cisplatin (CDDP)in patients with locoregionally advanced head and neck cancer.
- Trial name
- NCT01584284
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Genelux Corporation
Esophageal Cancer
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally…
- Trial name
- NCT04426955
- Testing
- Camrelizumab, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 396 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cervical Cancer
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous…
- Trial name
- NCT04693234
- Testing
- Tislelizumab, Ociperlimab
- Where
- 68 sites in Bulgaria, China and 6 more
- Volunteers
- 178 people
- Sponsor
- BeiGene
Infections, Papillomavirus, Cervical Cancer
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
The aim of the study is to assess the distribution of the most frequent types of human papillomavirus in African women diagnosed with invasive cervical cancer.
- Trial name
- NCT01207999
- Testing
- Collection of cervical cancer tissue samples, Data collection
- Where
- 5 sites in Ghana, Nigeria and 1 more
- Volunteers
- 591 people
- Sponsor
- GlaxoSmithKline
Advanced/Metastatic Solid Tumors, Bladder Cancer
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07090499
- Testing
- PF-08046876, Pembrolizumab, Cisplatin
- Where
- 31 sites in United States, Canada and 4 more
- Volunteers
- 540 people
- Sponsor
- Pfizer
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with recurrent / metastatic advanced endometrial cancer, cervical cancer and ovarian cancer with PIK3CA and / or PIK3R1 / 2 gene-altered (mutation or…
- Trial name
- NCT04836663
- Testing
- TQ-B3525 tablet
- Where
- 5 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Oral Mucositis
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the duration or length of severe oral mucositis in patients with head and neck cancers.
- Trial name
- PREVLAR (NCT03515538)
- Testing
- RRx-001, Cisplatin for injection, Radiation Therapy
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- EpicentRx, Inc.
Cancer-related Fatigue
A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy
Eighty to 90% of SCCHN (squamous cell carcinoma of head and neck) patients in Taiwan were betel quid chewers. Thirty to 40% of them experienced mucositis World Health Organization (WHO) grade 3 from cisplatin/flurouracil (FU) in…
- Trial name
- NCT01720563
- Testing
- Astragalus polysaccharides 500 mg, Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
- Where
- Taiwan
- Volunteers
- 17 people
- Sponsor
- PhytoHealth Corporation
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.